CRISPR targeting of SNPs associated with age-related macular degeneration in ARPE-19 cells: a potential model for manipulating the complement system
Salman A. et al, (2025), Gene Therapy, 32, 132 - 141
Gene Therapies in Clinical Development to Treat Retinal Disorders
McClements ME. et al, (2024), Molecular Diagnosis & Therapy, 28, 575 - 591
Genetic therapies and potential therapeutic applications of CRISPR activators in the eye.
Ng BW. et al, (2024), Prog Retin Eye Res, 102
Single-cell transcriptomic analysis of retinal immune regulation and blood-retinal barrier function during experimental autoimmune uveitis
Quinn J. et al, (2024), Scientific Reports, 14
Rescue of cone and rod photoreceptor function in a CDHR1-model of age-related retinal degeneration
Yusuf IH. et al, (2024), Molecular Therapy, 32, 1445 - 1460
CRISPR Manipulation of Age-Related Macular Degeneration Haplotypes in the Complement System: Potential Future Therapeutic Applications/Avenues
Salman A. et al, (2024), International Journal of Molecular Sciences, 25, 1697 - 1697
Programmable RNA editing with endogenous ADAR enzymes – a feasible option for the treatment of inherited retinal disease?
Bellingrath J-S. et al, (2023), Frontiers in Molecular Neuroscience, 16
A Review of CRISPR Tools for Treating Usher Syndrome: Applicability, Safety, Efficiency, and In Vivo Delivery.
Major L. et al, (2023), Int J Mol Sci, 24
Erratum: Enhancement of Adeno-Associated Virus-Mediated Gene Therapy Using Hydroxychloroquine in Murine and Human Tissues.
Chandler LC. et al, (2023), Mol Ther Methods Clin Dev, 28
Future Perspectives of Prime Editing for the Treatment of Inherited Retinal Diseases.
Hansen S. et al, (2023), Cells, 12
Impaired glutamylation of RPGR ORF15 underlies the cone-dominated phenotype associated with truncating distal ORF15 variants
Cehajic-Kapetanovic J. et al, (2022), Proceedings of the National Academy of Sciences, 119
Minicircle Delivery to the Neural Retina as a Gene Therapy Approach
Staurenghi F. et al, (2022), International Journal of Molecular Sciences, 23, 11673 - 11673
New CRISPR Tools to Correct Pathogenic Mutations in Usher Syndrome.
Major L. et al, (2022), Int J Mol Sci, 23
Non-Viral Delivery of CRISPR/Cas Cargo to the Retina Using Nanoparticles: Current Possibilities, Challenges, and Limitations
Salman A. et al, (2022), Pharmaceutics, 14, 1842 - 1842
CRISPR DNA Base Editing Strategies for Treating Retinitis Pigmentosa Caused by Mutations in Rhodopsin
Kaukonen M. et al, (2022), Genes, 13, 1327 - 1327
AAV2-mediated gene therapy for Bietti crystalline dystrophy provides functional CYP4V2 in multiple relevant cell models.
Wang J-H. et al, (2022), Sci Rep, 12
Envisioning the development of a CRISPR-Cas mediated base editing strategy for a patient with a novel pathogenic CRB1 single nucleotide variant.
Bellingrath J-S. et al, (2022), Ophthalmic Genet, 1 - 10
Tropism of AAV Vectors in Photoreceptor-Like Cells of Human iPSC-Derived Retinal Organoids.
McClements ME. et al, (2022), Transl Vis Sci Technol, 11
The Scope of Pathogenic ABCA4 Mutations Targetable by CRISPR DNA Base Editing Systems—A Systematic Review
Piotter E. et al, (2022), Frontiers in Genetics, 12